Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Beats Expectations By $0.28 EPS

Eton Pharmaceuticals (NASDAQ:ETON) issued its quarterly earnings results on Thursday. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.28, FiscalAI reports. The company had revenue of $37.59 million for the quarter, compared to analysts’ expectations of $27.11 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.

Eton Pharmaceuticals Price Performance

Shares of ETON stock traded down $0.78 on Thursday, reaching $40.80. The company had a trading volume of 568,966 shares, compared to its average volume of 396,114. The business’s 50-day moving average is $38.23 and its 200 day moving average is $28.20. Eton Pharmaceuticals has a one year low of $14.27 and a one year high of $50.18. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $1.12 billion, a PE ratio of -582.77 and a beta of 0.86.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $65 price target, implying potential upside from recent trading levels. The analyst still expects Eton’s earnings to grow substantially over time, reaching $6.53 per share in 2030. HC Wainwright analyst coverage
• Neutral Sentiment: HC Wainwright projected a progression in annual EPS from $0.52 in 2026 to $1.28 in 2027, $2.23 in 2028, $4.25 in 2029 and $6.53 in 2030. The estimates suggest continued long-term growth, but they are below the firm’s previous forecasts. Eton Pharmaceuticals earnings estimates
• Neutral Sentiment: Reported short-interest data showed zero shares sold short as of August 11, unchanged from the prior period. However, the figures appear anomalous and provide little meaningful information about current trading pressure. Eton Pharmaceuticals short interest
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to $0.52 from $0.68 and reduced quarterly forecasts for Q2 2026 to $0.11 from $0.15, Q3 to $0.17 from $0.23 and Q4 to $0.19 from $0.25. The firm also lowered its FY2027 EPS estimate to $1.28 from $1.83, FY2028 to $2.23 from $3.50, FY2029 to $4.25 from $5.85 and FY2030 to $6.53 from $8.65. These sizable reductions signal a more cautious view of Eton’s future profitability and may weigh on the shares. HC Wainwright estimate reductions

Insider Activity at Eton Pharmaceuticals

In related news, insider David Krempa sold 19,679 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13. Following the completion of the transaction, the insider directly owned 25,249 shares in the company, valued at $794,586.03. This represents a 43.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jennifer Mckie Adams sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 150,000 shares of company stock worth $4,853,921 over the last ninety days. 16.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Quarry LP acquired a new position in Eton Pharmaceuticals in the 3rd quarter worth about $37,000. Legal & General Group Plc acquired a new stake in shares of Eton Pharmaceuticals during the second quarter valued at about $41,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth about $44,000. New York State Common Retirement Fund bought a new stake in shares of Eton Pharmaceuticals during the second quarter worth about $115,000. Finally, State of Wyoming increased its stake in shares of Eton Pharmaceuticals by 50.0% in the fourth quarter. State of Wyoming now owns 8,161 shares of the company’s stock valued at $138,000 after buying an additional 2,721 shares during the period. Institutional investors and hedge funds own 27.86% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ETON. Zacks Research cut shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Craig Hallum upped their price target on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. HC Wainwright upped their target price on Eton Pharmaceuticals from $57.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.50.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.